Can engineered immune cells tackle brain lymphoma?
NCT ID NCT04443829
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This early-phase trial is testing a type of immunotherapy called CD19CAR T-cells in people aged 16 and older with relapsed or refractory primary CNS lymphoma, a rare cancer of the brain or spinal cord. The treatment involves collecting a patient's own immune cells, engineering them to recognize and attack cancer cells, and infusing them back into the patient. The study aims to see if this approach is safe, feasible to manufacture, and whether the engineered cells can expand and persist in the body to fight the lymphoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19CAR T-cells (a type of immunotherapy where a patient's own immune cells are engineered to target and attack cancer cells)
- What this could lead to
- If successful, this could offer a new treatment option for a hard-to-treat brain lymphoma that has returned or not responded to standard therapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not be conclusive. There is a risk of severe side effects, including immune reactions that can be serious or life-threatening.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University College London Hospital
London, WC1E6BT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.